Moderna Announces Success of mRNA-1283 in Phase 3 Vaccine Trial
Thursday, 13 June 2024, 12:04
Moderna's mRNA-1283 Success
Moderna has reported positive results from the phase 3 trial of its next-generation COVID-19 vaccine, mRNA-1283.
Primary Efficacy Endpoint Met
Moderna announced that mRNA-1283 has successfully met its primary efficacy endpoint in the trial.
These results hold significant promise for combating the current global health crisis and advancing vaccination efforts.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.